Alirocumab is a fully human monoclonal antibody to PCSK9. The ODYSSEY MONO study was the first alirocumab Phase III study to test a previously unused dose of 75 mg subcutaneously every 2 weeks in ...

Sanofi and Regeneron have announced positive results from trials of novel drug alirocumab, which targets PCSK9, in people with hypercholesterolemia. The results of the four phase III ODYSSEY ...